Compare Teladoc Health Inc (TDOC) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teladoc Health Inc vs Zoetis Inc — how do they compare? Teladoc Health Inc trades at $5.77 (market cap $1.01B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 29.9× Teladoc Health Inc's market cap, and Zoetis Inc pays a 2.9% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Teladoc Health Inc for 39 Days and Zoetis Inc for 70 Days on average.
| TDOC | ZTS | |
|---|---|---|
Market Cap | $1.01B | $30.20B |
Volume | 4,668,477 | 6,175,327 |
Sector | Health | Health |
52-Week High | $9.72 | $147.53 |
52-Week Low | $4.47 | $69.09 |
Typical Hold Time | 39 Days | 70 Days |
Enterprise Value | $1.27B | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Teladoc Health (TDOC) trades at $5.54, down 0.36% on the day, as the stock faces bearish technical momentum despite recent earnings beats. The company maintains strong revenue around $2.5B annually but continues to report net losses, with a -7.13% net income margin in 2026. Analyst sentiment is mixed with 35.7% buy ratings but a consensus price target of $8.83 suggesting 59% upside potential. Recent CFO appointment and legal officer transitions signal management changes amid ongoing operational challenges.
TDOC presents a high-risk opportunity with significant valuation discount (P/S 0.4x) but faces persistent profitability challenges. The integrated care business shows promise with improving margins, while BetterHelp weakness and negative cash flow in 2025 raise concerns. Upside depends on successful execution of turnaround strategy and achieving sustainable profitability in the competitive telehealth market.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.
The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
